SCHEMBL6420439

SCHEMBL6420439

CC(=O)C(C)(C)NC(=O)c1ccc(F)cc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.52
CES1 P23141 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.48
SNCA P37840 1/20 0.46
HDAC1 Q13547 1/20 0.45
RAB9A P51151 4/20 0.44
NPC1 O15118 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
TP53 P04637 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
GAA P10253 2/20 0.43
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
MAPK14 Q16539 1/20 0.41
POLB P06746 1/20 0.41
APEX1 P27695 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
AVPR2 P30518 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6433698 0.89 CES2 (0.50) CES2CES1L3MBTL1SNCAHDAC1
SCHEMBL6416783 0.87 CES2 (0.49) CES2CES1L3MBTL1SNCAHDAC1
SCHEMBL6419619 0.86 POLB (0.56) CES2CES1L3MBTL1SNCAHDAC1
SCHEMBL6417004 0.86 CES2 (0.47) CES2CES1L3MBTL1SNCAHDAC1
SCHEMBL28451463 0.82 CES2 (0.44) CES2CES1L3MBTL1SNCAHDAC1
SCHEMBL6419694 0.81 CNR2 (0.54) CES2CES1L3MBTL1SNCARAB9A
SCHEMBL6419870 0.81 CES2 (0.49) CES2CES1L3MBTL1SNCAHDAC1
SCHEMBL6418339 0.81 KDM4E (0.51) CES2CES1L3MBTL1SNCARAB9A
SCHEMBL6416032 0.81 CES2 (0.49) CES2CES1L3MBTL1SNCAHDAC1
SCHEMBL28897979 0.80 L3MBTL1 (0.43) CES2CES1L3MBTL1SNCARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936736-B2 Amide derivative SUMITOMO MANUFACTURING COMPANY LIMITED (JP) 2005-08-30 US disclosed
EP-1034783-B1 AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS SUMITOMO PHARMA (JP) 2004-12-15 EP disclosed
US-20020147204-A1 Amide derivative SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2002-10-10 US disclosed
US-6384033-B1 DRUGS FOR VISION DEFECTS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-05-07 US disclosed
EP-1034783-A1 AMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2000-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147204-A1 Amide derivative ALDH1A2, NR1H2, HDAC3 CES2 3713/4885CES1 1026/4885L3MBTL1 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.